Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

NCT05691504 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05691504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05691504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 14, 2023
Completion date
February 1, 2027
Enrollment
42 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial carcinoma, metastatic endometrial carcinoma, metastatic fallopian tube carcinoma, metastatic platinum-resistant ovarian carcinoma, metastatic primary peritoneal carcinoma, recurrent endometrial carcinoma, recurrent fallopian tube carcinoma, recurrent platinum-resistant ovarian carcinoma, recurrent primary peritoneal carcinoma, stage iii uterine corpus carcinoma or carcinosarcoma ajcc v8, stage iv uterine corpus carcinoma or carcinosarcoma ajcc v8